Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC : a retrospective chart review (REFLECT)
Authors:Addeo, Alfredo (Author)
Hochmair, Maximilian J (Author)
Janžič, Urška (Author)
Dudnik, Elizabeth (Author)
Charpidou, Andriani (Author)
Płużański, Adam (Author)
Ciuleanu, Tudor (Author)
Shterev Donev, Ivan (Author)
Elbaz, Judith (Author)
Aarøe, Jørgen (Author)
Ott, René (Author)
Peled, Nir (Author)
Language:English
Tipology:1.01 - Original Scientific Article
Organisation:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first results of a real-world observational study on the effectiveness of ICI monotherapy in patients with advanced NSCLC treated at a single academic center in a Central and Eastern European (CEE) country. Materials and methods. Overall, 66 consecutive patients with advanced NSCLC treated with ICIs in everyday clinical practice, either with first-line pembrolizumab (26 patients) or second-line atezolizumab, nivolumab, or pembrolizumab (40 patients), from August 2015 to November 2018, were included. All data were retrieved from a hospital lung cancer registry, in which the data is collected prospectively. Results. Included patients had a median age of 64 years, most were male (55%), 6% were in performance status >/=2, and 18% had controlled central nervous system metastases at baseline. In first-line, the median progression-free survival (mPFS) was 9.3 months, while the median overall survival (mOS) was not reached. The 1-year overall survival (OS) was 62%. In second-line, the mPFS and mOS were 3.5 months and 9.9 months, respectively, with a 1-year OS of 35%. In the overall population, adverse events of any grade were recorded in 79% of patients and of severe grade (3-4) in 12% of patients. Conclusion. The first real-world outcomes of NSCLC immunotherapy from a CEE country suggest comparable effectiveness to those observed in clinical trials and other real-world series, mainly coming from North America and Western European countries. Further data to inform on the real-world effectiveness of immunotherapy worldwide are needed.
Keywords:non-small cell lung carcinoma, immunotherapy, advanced non-small cell lung cancer, real-world data, Europe, Central Europe, Eastern Europe
Year of publishing:2021
Publisher:Sage
Source:Velika Britanija
COBISS_ID:89318403 Link is opened in a new window
UDC:616-006
ISSN on article:1758-8359
DOI:10.1177/17588359211059874 Link is opened in a new window
Note:Nasl. z nasl. zaslona; Soavtorica iz Slovenije: Urška Janžič; Opis vira z dne 14. 12. 2021;
Views:248
Downloads:77
Files:URL URL - Source URL, visit https://journals.sagepub.com/doi/pdf/10.1177/17588359211059874
 
Journal:Ther. adv. med. oncol.
SAGE Publications
 
Metadata:XML RDF-CHPDL DC-XML DC-RDF
Rights:© The Author(s), 2021
:
  
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


Licences

License:CC BY-NC 4.0, Creative Commons Attribution Non-Commercial 4.0 International
Link:http://creativecommons.org/licenses/by-nc/4.0/
Description:A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.
Licensing start date:27.10.2021

Back